1-Ethyl-3-t-butylhexahydropyrimidin | 28286-15-9

• 分子结构分类: 有机化合物 - 有机杂环化合物 - 二嗪烷类
• 英文名称: 1-Ethyl-3-t-butylhexahydropyrimidin
• 英文别名: 3-tert-Butyl-1-ethylhexahydropyrimidin；1-tert-Butyl-3-ethyl-hexahydropyrimidin；1-tert-butyl-3-ethyl-hexahydro-pyrimidine；1-Tert-butyl-3-ethyl-1,3-diazinane
• CAS: 28286-15-9
• 化学式: C₁₀H₂₂N₂
• 分子量: 170.298
• InChiKey: HUFNXSYUPPBVAH-UHFFFAOYSA-N

计算性质

• 辛醇/水分配系数(LogP)：
  1.9
• 重原子数：
  12
• 可旋转键数：
  2
• 环数：
  1.0
• sp3杂化的碳原子比例：
  1.0
• 拓扑面积：
  6.5
• 氢给体数：
  0
• 氢受体数：
  2

文献信息

• Modulators of Cellular Adhesion
  申请人：Shen Wang

  公开号：US20110124625A1

  公开（公告）日：2011-05-26

  The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R 1 -R 4 , n, p, A, B, D, E, L and AR 1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).

  本发明提供了具有式(I)的化合物及其药学上可接受的衍生物，其中R1-R4、n、p、A、B、D、E、L和AR1如本文中一般和各类和子类中所述，并且还提供了其药物组成物以及使用它们治疗由CD11/CD18细胞粘附分子（例如LFA-1）介导的疾病的方法。
• MODULATORS OF CELLULAR ADHESION
  申请人：SARcode Bioscience Inc.

  公开号：US20140051675A1

  公开（公告）日：2014-02-20

  The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R 1 -R 4 , n, p, A, B, D, E, L and AR 1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).

  本发明提供具有式(I)的化合物及其药学上可接受的衍生物，其中R1-R4、n、p、A、B、D、E、L和AR1的描述如本文中一般和各类和子类中所述，并且还提供了其药物组成物以及使用它们治疗由CD11/CD18细胞黏附分子（例如LFA-1）介导的疾病的方法。
• Modulators of cellular adhesion
  申请人：Shen Wang

  公开号：US20080176896A1

  公开（公告）日：2008-07-24

  The present invention provides compounds having formula (I): and pharmaceutically acceptable derivatives thereof, wherein R 1 -R 4 , n, p, A, B, D, E, L and AR 1 are as described generally and in classes and subclasses herein, and additionally provides pharmaceutical compositions thereof, and methods for the use thereof for the treatment of disorders mediated by the CD11/CD18 family of cellular adhesion molecules (e.g., LFA-1).
• ENOYL REDUCTASE INHIBITORS WITH ANTIBACTERIAL ACTIVITY
  申请人：Novalex Therapeutics, Inc.

  公开号：US20180072666A1

  公开（公告）日：2018-03-15

  The present disclosure provides FabI inhibitors and methods of treating or preventing a disease or disorder in a subject by administering same.
• US7314938B2
  申请人：——

  公开号：US7314938B2

  公开（公告）日：2008-01-01